BAYESIAN NETWORK META-ANALYSIS (NMA) TO ASSESS THE RELATIVE EFFICACY OF CANAGLIFLOZIN MONOTHERAPY OVER 26 WEEKS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

被引：1

作者：

Schroeder, M. ^{[1
]}

Taieb, V ^{[2
]}

Belhadi, D. ^{[2
]}

Seyla-Hammer, C. ^{[2
]}

Hemels, M. ^{[3
]}

Nielsen, A. T. ^{[3
]}

机构：

[1] Janssen Cilag UK, High Wycombe, Bucks, England

[2] Amaris London, London, England

[3] Janssen Cilag AS, Birker A D, Denmark

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 03期

关键词：

D O I：

10.1016/j.jval.2015.03.329

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PDB22

引用

页码：A56 / A56

页数：1

共 50 条

[21] Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis
Zhu, Miao
Guan, Ruifang
Ma, Guo
[J]. FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[22] ACHIEVEMENT OF GLYCAEMIC TARGETS WITH CANAGLIFLOZIN IN TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Diels, J.
Schubert, A.
Hamilton, G.
Canovatchel, W.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A598 - A598
[23] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Pfeifer, Michael
Townsend, Raymond
Davies, Michael J.
Vijapurkar, Ujjwala
Ren, Jimmy
[J]. DIABETES, 2016, 65 : A303 - A303
[24] Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) Compared with Other Basal Insulin Therapies in Patients with Type 2 Diabetes Mellitus (T2DM)-A Network Meta-analysis (NMA)
Wang, Hongwei
Zhang, Quanwu
Frois, Christian
Vlajnic, Aleksandra
Wu, Eric
Gerrits, Charles
Chou, Engels
[J]. DIABETES, 2015, 64 : A26 - A26
[25] Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Sulfonylurea (SU) Monotherapy: A CANVAS Substudy
Fulcher, Greg
Matthews, David
Perkovic, Vlado
Mahaffey, Kenneth W.
Weiss, Robert
Rosenstock, Julio
Capuano, George
Desai, Mehul
Shaw, Wayne
Vercruysse, Frank
Meininger, Gary
Neal, Bruce
[J]. DIABETES, 2013, 62 : A292 - A292
[26] Achievement of Diabetes-related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Blonde, Lawrence
Woo, Vincent
Mathieu, Chantal
Yee, Jacqueline
Vijapurkar, Ujjwala
Meininger, Gary
[J]. DIABETES, 2014, 63 : A284 - A284
[27] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Nyirjesy, Paul
Sobel, Jack
Fung, Albert
Gassmann-Mayer, Cristiana
Ways, Kirk
Usiskin, Keith
[J]. DIABETES, 2013, 62 : A276 - A276
[28] Pharmacokinetics (PK) and Pharmacodynamics (PD) of Canagliflozin (CANA) in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)
Tamborlane, William
Polidori, David
Di Prospero, Nicolas
[J]. DIABETES, 2017, 66 : A371 - A371
[29] Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM)
Usiskin, Keith
Leiter, Lawrence A.
Forst, Thomas
Polidori, David
Xie, John
Sha, Sue
[J]. DIABETES, 2014, 63 : A284 - A284
[30] Canagliflozin (CANA) Reduces Serum Uric Acid (SUA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Davies, Michael
Trujillo, Angelina
Vijapurkar, Ujjwala
Damara-Ju, C. V.
Meininger, Gary
[J]. DIABETES, 2014, 63 : A283 - A284

← 1 2 3 4 5 →